Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.69%
0%
10.69%
6 Months
73.44%
0%
73.44%
1 Year
134.63%
0%
134.63%
2 Years
504.17%
0%
504.17%
3 Years
245.24%
0%
245.24%
4 Years
225.84%
0%
225.84%
5 Years
211.78%
0%
211.78%
Nexstim Oyj for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
21.82%
EBIT Growth (5y)
14.89%
EBIT to Interest (avg)
-0.77
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.41
Sales to Capital Employed (avg)
1.02
Tax Ratio
0.55%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.39%
ROE (avg)
6.42%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
33.11
EV to EBIT
107.39
EV to EBITDA
107.39
EV to Capital Employed
20.30
EV to Sales
10.67
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.17%
ROE (Latest)
-8.90%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
7.20
9.50
-24.21%
Operating Profit (PBDIT) excl Other Income
-1.00
1.10
-190.91%
Interest
0.10
0.10
Exceptional Items
-0.00
0.00
Consolidate Net Profit
-1.30
1.30
-200.00%
Operating Profit Margin (Excl OI)
-166.20%
84.60%
-25.08%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is -24.21% vs 48.44% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is -200.00% vs 262.50% in Dec 2022
About Nexstim Oyj 
Nexstim Oyj
Pharmaceuticals & Biotechnology
Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
Company Coordinates 
Company Details
Elimaenkatu 9 B , HELSINKI None : 00510
Registrar Details






